Peritransplant Soluble CD30 as a Risk Factor for Slow Kidney Allograft Function, Early Acute Rejection, Worse Long-Term Allograft Function, and Patients’ Survival

Abstract EN

Background.

We aimed to determine whether serum soluble CD30 (sCD30) could identify recipients at high risk for unfavorable early and late kidney transplant outcomes.

Methods.

Serum sCD30 was measured on the day of kidney transplantation and on the 4th day posttransplant.

We assessed the value of these measurements in predicting delayed graft function, slow graft function (SGF), acute rejection (AR), pyelonephritis, decline of allograft function after 6 months, and graft and patient survival during 5 years of follow-up in 45 recipients.

Results.

We found the association between low pretransplant serum levels of sCD30 and SGF.

The absence of significant decrease of sCD30 on the 4th day posttransplant was characteristic for SGF, early AR (the 8th day–6 months), late AR (>6 months), and early pyelonephritis (the 8th day–2 months).

Lower pretransplant and posttransplant sCD30 predicted worse allograft function at 6 months and 2 years, respectively.

Higher pretransplant sCD30 was associated with higher frequency of early AR, and worse patients’ survival, but only in the recipients of deceased-donor graft.

Pretransplant sCD30 also allowed to differentiate patients with early pyelonephritis and early AR.

Conclusions.

Peritransplant sCD30 is useful in identifying patients at risk for unfavorable early and late transplant outcomes.